Treatment of Vascular, Autoimmune and Inflammatory Diseases Using Low Dosages of IMPDH Inhibitors

• US 20090088427A1
• Filed: 05/05/2008
• Published: 04/02/2009
• Est. Priority Date: 02/08/2005
• Status: Active Grant

• Current Assignee: Michael R. Hayden, Noel Hall, Richard Glickman
• Original Assignee: Michael R. Hayden, Noel Hall, Richard Glickman
• Inventors: GLICKMAN, Richard, Hayden, Michael R., Hall, Noel
• Granted Patent: US 8,957,071 B2
• Time in Patent Office: Days
• US Class Current: 514/233.500
• CPC Class Codes: A61K 31/343 condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• CPC Class Codes: A61K 31/365 Lactones
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The disclosure provides methods and compositions for treating a vascular, autoimmune, and/or inflammatory disease, or a condition associated therewith, with a dose of an inosine monophosphate dehydrogenase (IMPDH) inhibitor effective to treat the vascular, autoimmune and/or inflammatory disease, or associated condition but that does not produce immunosuppression sufficient to reduce the risk of allograft rejection. These lower doses of the immunosuppressant avoid the adverse consequences of severe immunosuppression while providing effective treatment of the vascular, autoimmune and/or inflammatory disease.

Claims

1. A method of treating a vascular, autoimmune and/or inflammatory disease, or a condition associated therewith, comprising administering to a human subject an amount of an IMPDH inhibitory compound selected from MPA, MMF, and combinations thereof that is effective to treat or reduce the risk of the vascular, autoimmune and/or inflammatory disease, or a condition associated therewith, but that does not produce immunosuppression sufficient to reduce the risk of allograft rejection.

2. The method of claim 1 in which the compound is MMF.

3. The method of claim 1 in which the daily amount of compound administered corresponds to a low dose.

4. The method of claim 1 in which the daily amount of compound administered corresponds to an extra-low dose.

5. The method of claim 1 in which the daily amount of compound administered corresponds to an ultra-low dose.

6. The method of claim 1 in which the disease is a vascular disease.

7. The method of claim 6 in which the vascular disease is atherosclerosis, coronary heart disease (CHD), cardiovascular disease (CVD), coronary artery disease (CAD), cerebrovascular disease, or peripheral vascular disease.

8. The method of claim 1 in which the disease is an autoimmune disease.

9. The method of claim 8 in which the autoimmune disease is systemic lupus erythematosus (SLE), multiple sclerosis (MS), diabetes mellitus, or rheumatoid arthritis (RA).

10. The method of claim 1 in which the condition treated is associated with autoimmune disease.

11. The method of claim 10 in which the condition associated with the autoimmune disease is atherosclerosis.

12. The method of claim 10 in which the condition associated with the autoimmune disease is an inflammatory condition.

13. The method of claim 1 in which the disease is an inflammatory disease.

14. The method of claim 13 in which the inflammatory disease is vasculitis, Crohn'"'"'s disease, ulcerative colitis, or inflammatory bowel disease.

15. The method of claim 1 in which the compound is administered orally.

16. The method of claim 15 in which the compound is administered once per day.

17. The method of claim 15 in which the compound is administered twice per day.